Jiangsu Nuohe Bituo

Nuohe Bituo is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation peptide therapeutics for metabolic and cardiovascular diseases. The company utilizes its proprietary technology platforms for long-acting peptide modification and oral drug delivery to create differentiated treatments for conditions such as obesity and type 2 diabetes. Its lead candidate, NHBT-001, is a dual GLP-1/GIP receptor agonist currently undergoing clinical evaluation. Headquartered in Taizhou, China, the company is backed by prominent venture capital firms and aims to address significant unmet needs in the global metabolic health market.